Ali Eastburn was looking forward to her son's wedding when her side-effects from weight loss drugs went from bad to worse ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

People enrolled in the military health care benefits program Tricare for Life no longer will be eligible for coverage of ...

Eli Lilly’s orforglipron cut body weight to a lesser extent than rival Novo Nordisk’s semaglutide, falling into analysts’ ...

Eli Lilly stock plunges. To find out what lies ahead for Eli Lilly in this increasingly competitive environment, visit CDS.

Today’s Forbes Daily covers Eli Lilly’s historic loss, the new GPT-5 for OpenAI’s ChatGPT, reactions to Instagram’s new map ...

In the U.S. where adoption is highest, fewer than 1 in 10 adults are on a GLP-1 drug, despite nearly three-quarters being overweight or obese. Globally access is even more limited, held back by high ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Novo Nordisk's Canadian patent for weight loss drug Ozempic is set to expire in January 2026. Dr. Justin Ezekowitz discusses generic competitors that may come.

A series of lawsuits have been filed in Marion County court alleging that drug manufacturer Eli Lilly downplayed the side ...

Duolingo (DUOL) stock is surging on a strong second quarter beat and raised guidance. Eli Lilly (LLY) stock is plunging as ...